Match Document Document Title
US20140186468 DIAGNOSING SUBSETS OF TRIPLE-NEGATIVE BREAST CANCER  
The present invention provides a unique combination of biomarkers that identify triple-negative breast cancer (TNBC) patient subpopulations. Such subpopulations will have differential responses to...
US20140100185 UNIT DOSAGE OF APADENOSON  
The present invention provides a unit dosage of Apadenoson, a pharmacological stress agent, and use of the same as a pharmacologic agent for myocardial perfusion imaging.
US20130017153 UNIT DOSAGE OF APADENOSON  
The present invention provides a unit dosage of Apadenoson, a pharmacological stress agent, and use of the same as a pharmacologic agent for myocardial perfusion imaging.
US20130059802 BORON-CONTAINING SMALL MOLECULES  
This invention relates to compounds useful for treating fungal infections, more specifically topical treatment of onychomycosis and/or cutaneous fungal infections. This invention is directed to...
US20110015145 CLADRIBINE FORMULATIONS FOR IMPROVED ORAL AND TRANSMUCOSAL DELIVERY  
Provided are compositions of cladribine and cyclodextrin which are especially suited for the oral and buccal administration of cladribine.
US20110207689 THE TREATMENT OF HEARING LOSS  
The invention provides a method of treating noise-induced hearing loss, the method including the step of administering an A1 adenosine receptor agonist to a patient in need thereof. In a...
US20110110914 METHODS FOR TREATMENT OF ONCOLOGICAL DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS  
Methods and formulations for treating oncological disorders in humans using epimetabolic shifters, multidimensional intracellular molecules or environmental influencers are described.
US20140235562 COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS  
A method of treating an ocular disorder in a subject includes administering to the subject a therapeutically effective amount of an agent that modulates at least one target in a signaling cascade...
US20140248270 METHOD FOR TOPICAL TREATMENT OF TAR-RESPONSIVE DERMATOLOGICAL DISORDERS  
A method of treating a tar-responsive dermatological disorder includes topically applying an anhydrous tar composition to skin of a mammal, preferably a human, that is involved with the disorder,...
US20150010472 METHOD OF USING ADENOSINE AND DIPYRIDAMOLE FOR PHARMACOLOGIC STRESS TESTING, WITH SPECIFIC COMPOSITIONS, UNIT DOSAGE FORMS AND KITS  
Methods for detecting the presence and/or assessing the severity of myocardial ischemia during pharmacologic stress tests by administration of a pharmaceutical composition comprising adenosine and...
US20150202304 ENCAPSULATION OF IMMISCIBLE PHASES IN SILK FIBROIN BIOMATERIALS  
Embodiments of various aspects described herein relates to compositions and methods for encapsulation and/or stabilization of oil, lipid, hydrophobic and/or lipophilic compounds in a silk-based...
US20120134945 A3 ADENOSINE RECEPTOR LIGANDS FOR MODULATION OF PIGMENTATION  
The present invention relates to compositions and methods for modulating melanin production, secretion and/or accumulation in human skin cells. In particular, the present invention relates to the...
US20110028421 Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals  
The invention relates to the use of alkylphosphocholines in combination with antimetabolites for the treatment of multiple myeloma, colon cancer or renal cancer. Preferred alkylphosphocholines are...
US20130123208 METHOD OF TREATING MULTIPLE SCLEROSIS WITH ADENOSINE RECEPTOR AGONISTS  
The present invention includes a composition comprising an A2A agonist. The present invention also includes a method of treating or reducing the symptoms of a neuroinflammatory disease in a...
US20120027723 TAURINE OR TAURINE-LIKE SUBSTANCES FOR THE PREVENTION AND TREATMENT OF A DISEASE ASSOCIATED WITH RETINAL GANGLION CELL DEGENERATION  
The present invention relates to taurine or taurine-like substances for the prevention and treatment of a disease associated with retinal ganglion cell degeneration. More particularly the...
US20140370108 Pharmacokinetics of S-Adenosylmethionine Formulations  
Compositions and methods to improve the pharmacokinetic profile of S-Adenosylmethionine (SAMe) are provided, as are methods of treating various disorders using SAMe formulations with improved...
US20130149350 Pharmacokinetics of S-Adenosylmethionine Formulations  
Compositions and methods to improve the pharmacokinetic profile of S-Adenosylmethionine (SAMe) are provided, as are methods of treating various disorders using SAMe formulations with improved...
US20130129792 Pharmacokinetics of S-Adenosylmethionine Formulations  
Compositions and methods to improve the pharmacokinetic profile of S-Adenosylmethionine (SAMe) are provided, as are methods of treating various disorders using SAMe formulations with improved...
US20110027360 PHARMACOKINETICS OF S-ADENOSYLMETHIONINE FORMULATIONS  
Compositions and methods to improve the pharmacokinetic profile of S-Adenosylmethionine (SAMe) are provided, as are methods of treating various disorders using SAMe formulations with improved...
US20140005137 TISSUE MAINTENANCE  
The invention provides a method of reducing damage to a tissue, organ or cell from surgical procedures comprising administering a composition comprising a potassium channel opener/agonist and/or...
US20110064712 Dietary Supplement Compositions and Methods of Making and Using the Same  
Dietary supplement compositions are disclosed. Methods of making and using dietary supplement compositions are also disclosed.
US20150050332 IMPLANTABLE LIPOSOME EMBEDDED MATRIX COMPOSITION, USES THEREOF, AND POLYCAPROLACTONE PARTICLES AS SCAFFOLDS FOR TISSUE REGENERATION  
In various embodiments, the present invention describes materials and methods for the local reprogramming of cells in a location where the treatment is applied. The invention can be used to...
US20150038448 COMBINATION, KIT AND METHOD OF REDUCING INTRAOCULAR PRESSURE  
The present invention is directed to a combination or a kit comprising a prostaglandin analog and an adenosine receptor A1 agonist and to a method of reducing intraocular pressure (IOP) in a...
US20110172177 COMBINATION, KIT AND METHOD OF REDUCING INTRAOCULAR PRESSURE  
The present invention is directed to a combination or a kit comprising a prostaglandin analog and an adenosine receptor A1 agonist and to a method of reducing intraocular pressure (IOP) in a...
US20120203147 VASODILATOR-ENHANCED CARDIOPULMONARY RESUSCITATION  
A method for increasing blood flow to vital organs during cardiopulmonary resuscitation of a person experiencing a cardiac arrest may include performing standard or active compression...
US20110077215 DNA Methylation As A Target For Diagnosis And Treatment Of Chronic Lymphocytic Leukema (CLL)  
Global DNA methylation is a predictor of aggressive disease in patients with chronic lymphocytic leukemia. The higher the DNA methylation, the more likely a patient is going to require systemic...
US20130156872 Integrated Neuromodulation System for Mood Enhancement of a Living Human Subject  
The present invention is an ingestable blended formulation which will cause a series of distinct biochemical changes in-vivo; initiate desirable psychological consequences in that person; and...
US20120252750 FORMULATIONS FOR REDUCING NEURONAL DEGENERATION  
Nutriceutical and pharmaceutical formulations for treating neurodegenerative disorders such as Alzheimer's disease are provided. Nutriceutical formulations include two or more of folate, vitamin...
US20110014204 Cancer Chemoprevention Strategy Based on Loss of Imprinting of IGF2  
The present invention relates to targets of loss of imprinting (LOI) affected IGF2 gene products in pre-malignant tissues, where methods of inhibiting those targets, including IGFR1, are disclosed...
US20120270829 USE OF ADENOSINE A3 RECEPTOR AGONISTS FOR TREATMENT OF NEUROPATHIC PAIN  
A method of treating neuropathic pain in a subject is provided. The method comprises administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of an...
US20080312180 Methods to Protect Skeletal Muscle Against Injury  
Disclosed herein are compositions and methods for the treatment of skeletal muscle and/or the protection of skeletal muscle against injury. The adenosine A3 receptor has been identified as a new...
US20150038445 METHODS AND COMPOSITIONS FOR TREATING PAIN  
The disclosure provides a new use of adenosine analogs for the treatment of pain through activation of neurokinin 1 (NK1) receptor signaling pathway, thereby inducing the activation of M-type...
US20110110933 ECTOPIC PREGNANCY TREATMENT  
The invention pertains to methods for treating ectopic pregnancy. More particularly, the present invention relates to methods for treating unruptured ectopic pregnancy using a non-surgical method...
US20150018299 TREATMENT OF LIVER CONDITIONS  
The present disclosure concerns the A3 adenosine receptor agonist, 2-Chloro-N6-(3-iodobenzyl)-adenosine-5′-N-methyluronamide (Cl-IB-MECA) in an amount of at least about 10 mg/day, for use in...
US20140205680 METHODS OF USING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID FOR TREATMENT OF CANCER  
Methods of treating, preventing or managing cancer, including certain leukemias are disclosed. The methods encompass the administration of enantiomerically pure...
US20100317610 Methods and Compositions for Inducing Deregulation of EPHA7 and ERK Phosphorylation in Human Acute Leukemias  
Methods for assessing a pathological condition in a subject include measuring one or more markers where a difference is indicative of acute lymphoblastic leukemia (ALL) or a predisposition to ALL,...
US20100317611 METHODS, COMPOSITIONS, UNIT DOSAGE FORMS, AND KITS FOR PHARMACOLOGIC STRESS TESTING WITH REDUCED SIDE EFFECTS  
Methods are presented that comprise the administration of a pharmaceutical composition comprising adenosine and dipyridamole, as well methods comprising the combined administration of dipyridamole...
US20140004082 METHODS FOR TREATING LEUKEMIA AND DISORDERS MEDIATED BY CBFBETA AND RUNX1 PROTEINS  
A method for treating core binding factor (CBF) leukemia in a subject, comprising administering to a subject having CBF leukemia a therapeutically effective amount of a compound, or a...
US20150080330 METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS  
Provided herein is a method of reducing intraocular pressure (IOP) in humans using N6-cyclopentyladenosine (CPA), CPA derivatives or prodrugs or enhanced cornea permeability formulations of CPA....
US20140018314 METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS  
Provided herein is a method of reducing intraocular pressure (IOP) in humans using N6-cyclopentyladenosine (CPA), CPA derivatives or prodrugs or enhanced cornea permeability formulations of CPA....
US20110245195 METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS  
Provided herein is a method of reducing intraocular pressure (IOP) in humans using N6-cyclopentyladenosine (CPA), CPA derivatives or prodrugs or enhanced cornea permeability formulations of CPA....
US20110110891 Methods of Treating Hepatitis C Virus Infection  
The present disclosure provides methods of treating a hepatitis C virus infection. The methods generally involve administering to an individual in need thereof an effective amount of an active...
US20130281400 Metabolic Downregulation for Cell Survival  
The present provides a system and method of maintaining and/or increasing cell viability by downregulating cellular metabolic rate under hypoxic conditions. The present invention also relates to a...
US20130315862 METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS  
A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a...
US20130149283 METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS  
A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a...
US20130017171 METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS  
A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a...
US20110152215 RIBOSWITCHES, METHODS FOR THEIR USE, AND COMPOSITIONS FOR USE WITH RIBOSWITCHES  
It has been discovered that certain natural mRNAs serve as metabolite-sensitive genetic switches wherein the RNA directly binds a small organic molecule. This binding process changes the...
US20150038446 COMPOSITIONS AND METHODS FOR TREATING RETINAL DEGRADATION  
The present disclosure relates to compositions and methods for treating retinal damage and/or retinal degradation. More specifically, this disclosure relates to methods for treating degradation of...
US20130224170 METHOD OF AMELIORATING OXIDATIVE STRESS AND SUPPLEMENTING THE DIET  
A method of supplementing a diet and ameliorating oxidative stress in a mammal includes administering a pharmaceutically effective amount of lipid soluble, hydrophobic active compounds having a...
US20130108605 METHOD OF AMELIORATING OXIDATIVE STRESS AND SUPPLEMENTING THE DIET  
A method of supplementing a diet and ameliorating oxidative stress in a mammal includes administering a pharmaceutically effective amount of lipid soluble, hydrophobic active compounds having a...